Zentalis Closes $150 Million Secondary Offering for US-China Operations
publication date: Jul 1, 2021
Zentalis Pharma, a US-China biopharma, closed a $150 million secondary offering to advance its small molecule cancer portfolio. One year ago, Zentalis formed a a Shanghai subsidiary, Zentera Therapeutics, with initial funding of $20 million to develop three of its candidates in China. Zentalis owns a majority stake in the JV. A clinical stage company, Zentalis says its candidates target fundamental biological pathways of cancers. Zentalis is headquartered in New York City with labs in San Diego. More details....
Stock Symbol: (NSDQ: ZNTL)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.